Abstract
Successful tumor immunotherapy with peptides requires the induction of cytotoxic T lympho-cytes (CTLs) rather than antibodies. Mice immunized with mannan conjugated to MUC1, a pep-tide found in large amounts in breast cancer, develop CTL responses. In contrast, immunized patients produce high antibodies with poor CTL responses to MUC1. Here, we provide evidence that this “switch” in the immune response is due to the fact that antibodies against the Galα(1,3)Gal epitope, which are normally present in humans but not mice, cross-react with MUC1 peptides. In particular, mice that lack the gene for the epitope (and that produce anti-Gal antibodies) (Cal−/− mice) are like humans in their response to MUC1 immunization in that they develop antibody rather than CTL responses. After we exposed macrophages from Cal−/− mice in vitro to MUC1, in the absence of Gal antibody, and adoptively transferred them into the mice, Cal−/− mice produced a predominantly CTL response. The findings are of relevance for im-munotherapy studies in humans and emphasize the differences seen in preclinical testing in ro-dents before clinical trials.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Singer, A., Time and truth for cancer vaccines—a new generation. J. Natl. Cancer Inst. 86, 330–330 (1994).
Kawakami, Y. et al. Cloning of the gene coding for a shared human-melanoma anti-gen recognized by autologous T-cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA 91, 3515–3519 (1994).
Disis, M.L., Smith, J.W., Murphy, A.E., Chen, W., & Cheever, M.A. In vitro generation of human CTL specific for peptides derived from the Her-2/neu protooncogene pro-tein. Cancer Res. 54, 1071–1076 (1994).
Theobald, M., Biggs, J., Dittmer, D., Levine, A.J. & Sherman, L.A. Targeting p53 as a general tumor antigen. Proc. Natl. Acad. Sci. USA 92, 11993–11997 (1995).
Schendel, D.J. & Gansbacher, B. Tumor specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes: Modulation of recognition through retroviral transduction of tumor cells with interleukin 2 complementary DNA and exogenous alpha interferon treatment. Cancer Res. 53, 4020–4025 (1993).
Apostolopoulos, V., McKenzie, I.F.C. & Pietersz, G.A. Breast cancer immunother-apy—Current status and future prospects. Immunol. Cell Biol. 74, 457–464 (1996).
Apostolopoulos, V., Xing, P.X. & McKenzie, I.F.C. Murine immune response to cells transfected with human MUC1: Immunization with cellular and synthetic antigens. Cancer Res. 54, 5186–5193 (1994).
Apostolopoulos, V., Pietersz, G.A. & McKenzie, I.F.C. Cell-mediated immune re-sponses to MUC1 fusion protein coupled to mannan. Vaccine 14, 930–938 (1996).
Apostolopoulos, V., Pietersz, G.A., Loveland, B.E., Sandrin, M.S. & McKenzie, I.F.C. Oxidative/reductive conjugation of mannan to antigen selects for T, or T2 immune responses. Proc. Natl. Acad. Sci. USA 92, 10128–10132 (1995).
Karanikas, V. et al. Antibody and T cell responses of patients with adenocarcinoma im-munized with mannan-MUCI fusion protein. J. Clin. Invest. 100, 2738–2792 (1997).
Vaughan, H.A. et al. Recognition of an octapeptide sequence by multiple Galα(1,3)Gal-binding proteins. Xenotransplantation 3, 18–23 (1996).
Sandrin, M.S., Vaughan, H.A., Xing, P.X. & McKenzie, I.F.C. Natural human anti-Galα(1,3)Gal antibodies react with human mucin peptides. Glycoconj. J. 14, 97–105 (1997).
Sandrin, M.S., Vaughan, H.A., Dabkowski, P.L. & McKenzie, I.F.C. Anti-pig antibodies in human serum predominantly with Galα(1,3)Gal epitopes. Proc. Natl. Acad. Sci. USA 90, 11391–11395 (1995).
Vaughan, H.A., Loveland, B.E. & Sandrin, M.S. Galα(1,3)Gal is the major xenoepitope expressed on pig endothelial cells recognised by naturally occurring cytotoxic anti-bodies. Transplantation 58, 879–884 (1994).
McKenzie, I.F.C. et al. Distribution of the major xenoantigens (Galα(1,3)Gal) for pig to human xenografts. Transplant Immunol. 2, 81–86 (1994).
Galili, U. & La Temple, C. Natural anti-Gal antibody as a universal augmentor of au-tologous tumor vaccine immunogenicity. Immunol. Today 18, 281–285 (1997).
Celis, E., Abraham, K.G. & Miller, R.W. Modulation of the immunological response to hepatitis B virus by antibodies. Hepatology 7, 563–568 (1987).
Amigorena, S. et al. Cytoplasmic domain heterogeneity and functions of IgG Fc re-ceptors in B lymphocytes. Science 256,1801 1812 (1992).
Bouige, P., Iscaki, S., Cosson, A. & Pillot, J. Molecular analysis of the modulatory fac-tors of the response to HBsAg in mice as an approach to HBV vaccine enhancement. Immunol. Med. Microbiol. 13, 71–79 (1996).
Heijnen, I.A. et al. Antigen targeting to myeloid-specific human Fc gamma RI/CD64 triggers enhanced antibody responses in transgenic mice. J. Clin. Invest. 97, 331–338 (1996).
Molina, H. et al. Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proc. Natl. Acad. Sci. USA 93, 3357–3361 (1996).
Lefkovits, I. & Waldmann, H. Limiting dilution analysis of the cells of the immune sys-tem. I. The clonal basis of the immune response. Immunol. Today 5, 265–272 (1984).
Taswell, C. Limiting dilution assays for the determination of immunocompetent cell frequencies. J. Immunol. 126, 1614–1619 (1981).
Fazekas de St. Groth, S. The evaluation of limiting dilution assays [review]. J. Immunol. Methods 49, R11R23 (1982).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Apostolopoulos, V., Osinski, C. & Mckenzie, I. MUC1 cross-reactive Galα(l,3)Gal antibodies in humans switch immune responses from cellular to humoral. Nat Med 4, 315–320 (1998). https://doi.org/10.1038/nm0398-315
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nm0398-315